Ken Griffin Nuvalent, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Nuvalent, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 11,000 shares of NUVL stock, worth $909,150. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,000

Previous 61,700 82.17%

Holding current value

$909,150

Previous $4.68 Million 75.96%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$67.44 - $112.17 $16 Million - $26.6 Million	236,774 Added 4093.6%	242,558 $24.8 Million
Q2 2024 Aug 14, 2024	SELL	$62.76 - $81.61 $6.53 Million - $8.5 Million	-104,100 Reduced 94.74%	5,784 $438,000
Q1 2024 May 15, 2024	SELL	$72.35 - $88.99 $7.18 Million - $8.83 Million	-99,257 Reduced 47.46%	109,884 $8.25 Million
Q4 2023 Feb 14, 2024	BUY	$42.42 - $80.28 $8.86 Million - $16.8 Million	208,934 Added 100934.3%	209,141 $15.4 Million
Q3 2023 Nov 14, 2023	SELL	$39.12 - $49.85 $1.76 Million - $2.24 Million	-44,963 Reduced 99.54%	207 $9,000
Q2 2023 Aug 14, 2023	BUY	$23.58 - $44.68 $460,423 - $872,421	19,526 Added 76.14%	45,170 $1.9 Million
Q1 2023 May 15, 2023	BUY	$25.42 - $33.52 $645,922 - $851,743	25,410 Added 10858.97%	25,644 $669,000
Q4 2022 Feb 14, 2023	SELL	$18.46 - $36.37 $742,664 - $1.46 Million	-40,231 Reduced 99.42%	234 $6,000
Q3 2022 Nov 14, 2022	SELL	$13.55 - $19.92 $708,624 - $1.04 Million	-52,297 Reduced 56.38%	40,465 $787,000

Others Institutions Holding NUVL

# of Institutions

209

Shares Held

59.5M

Call Options Held

450K

Put Options Held

619K

View Full List

About Nuvalent, Inc.

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.55B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

More about NUVL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account